Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.

@article{Kakuda2008SingleAM,
  title={Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.},
  author={Thomas N Kakuda and Monika Sch{\"o}ller-Gy{\"u}re and Cassy Workman and Keikawus N. Arast{\'e}h and Anton L Pozniak and Goedele de Smedt and Greet I Beets and Monika Peeters and K. Y. Vandermeulen and Brian J Woodfall and Richard M. W. Hoetelmans},
  journal={Antiviral therapy},
  year={2008},
  volume={13 5},
  pages={
          655-61
        }
}
BACKGROUND An open-label, randomized, crossover study to evaluate the pharmacokinetics of two different formulations of etravirine after single and multiple dosing. METHODS Treatment-experienced HIV-1-infected patients with viral load <50 copies/ml continued their current antiretroviral regimen and added etravirine twice daily for 7 days with a morning intake on day 8. Etravirine was administered following food as either 800 mg twice daily of the Phase II formulation or 100 mg or 200 mg twice… CONTINUE READING

Similar Papers

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

No clinically relevant effect of etravirine on digoxin pharmacokinetics in HIV–negative volunteers

M Schöller-Gyüre, TN Kakuda, RM Van Solingen-Ristea
  • 9th International Workshop on Clinical Pharmacology of HIV Therapy
  • 2008
VIEW 1 EXCERPT

Pharmacokinetics and pharmacodynamics of the NNRTI TMC125 in treatment-experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET–2

TN Kakuda, JR Wade, E Snoeck
  • 15th Conference on Retroviruses and Opportunistic Infections;
  • 2008
VIEW 1 EXCERPT

Massbalance of 14C–labelled TMC125 in healthy volunteers

M Schöller-Gyüre, A Raoof, G Mannens
  • 6th International Workshop on Clinical Pharmacology of HIV Therapy
  • 2007
VIEW 1 EXCERPT

Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223

CJ Cohen, CR Steinhart, D Ward
  • XVI International AIDS Conference
  • 2006
VIEW 2 EXCERPTS